Literature DB >> 16904966

High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.

Shuwen Xu1, Ursula Koldovsky, Min Xu, Daniel Wang, Elizabeth Fitzpatrick, Gilsoo Son, Gary Koski, Brian J Czerniecki.   

Abstract

BACKGROUND: High-level production of heterodimeric p70 interleukin (IL)-12 by myeloid-derived dendritic cells (DCs) requires 2 signals: interferon gamma (IFN-gamma) and a maturation signal provided by CD40 ligation (CD40L) or lipopolysaccharide (LPS).
METHODS: In the current study we demonstrate that signaling through toll-like receptor (TLR) 8, but not TLR3, TLR2, or TLR4, provides a priming signal to myeloid-derived DC for high IL-12 p70 heterodimer production.
RESULTS: All the TLR agonists induced maturation of DC as evidenced by increased expression of CD83, CD80, and CD86. Both IFN-gamma and TLR7/8 agonist R848 increased expression of TLR8 in immature monocyte-derived DCs. The combination of TLR7/8 agonist R848 and maturation signals LPS or CD40L induced high-level expression of IL-12p35 and p40 similar to that induced by IFN-gamma plus LPS. In contrast, receptor agonists specific for TLR7 did not prime for IL-12 production. The p70 IL-12 produced by the TLR8-primed DC polarized CD4+ T for Th1 cytokine production and induced CD8+ T cells, displaying high functional avidity with enhanced tumor cell recognition.
CONCLUSIONS: The data suggest that toll 8 receptor agonists are useful for inducing type-1 polarized DCs for vaccine design in treating cancer and infectious disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904966     DOI: 10.1016/j.surg.2006.03.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection.

Authors:  Beth C Holbrook; Rama D Yammani; Lance K Blevins; Martha A Alexander-Miller
Journal:  Viral Immunol       Date:  2013-08-24       Impact factor: 2.257

2.  An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates.

Authors:  Beth C Holbrook; S Tyler Aycock; Emily Machiele; Elene Clemens; Danielle Gries; Matthew J Jorgensen; Mallinath B Hadimani; S Bruce King; Martha A Alexander-Miller
Journal:  Immunology       Date:  2017-10-24       Impact factor: 7.397

3.  CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.

Authors:  Zulkarnain Harfuddin; Shaqireen Kwajah; Adrian Chong Nyi Sim; Paul Anthony Macary; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2013-11-11       Impact factor: 8.110

4.  In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapy.

Authors:  Benedikt Gahn; Matthias Staudinger; Katrin Woester; Dominique Wellnitz; Sebastian Boettcher; Martin Gramatzki; Michael Kneba
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

5.  C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.

Authors:  Claudia Zannetti; François Bonnay; Fumihiko Takeshita; Peggy Parroche; Christine Ménétrier-Caux; Massimo Tommasino; Uzma A Hasan
Journal:  J Biol Chem       Date:  2010-09-09       Impact factor: 5.157

6.  Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.

Authors:  Hailing Lu; Yi Yang; Ekram Gad; Cynthia A Wenner; Amy Chang; Emily R Larson; Yushe Dang; Mark Martzen; Leanna J Standish; Mary L Disis
Journal:  Clin Cancer Res       Date:  2010-11-10       Impact factor: 12.531

7.  HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Authors:  Anupama Sharma; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Robert Roses; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Gary Koski; Brian J Czerniecki
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

Review 8.  Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Authors:  Robert E Roses; Jashodeep Datta; Brian J Czerniecki
Journal:  Radiat Res       Date:  2014-07-03       Impact factor: 2.841

9.  Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17.

Authors:  Christopher Paustian; Patricia Taylor; Terrence Johnson; Min Xu; Nancy Ramirez; Kenneth S Rosenthal; Suyu Shu; Peter A Cohen; Brian J Czerniecki; Gary K Koski
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR Stimulation.

Authors:  Kuo-Ching Sheng; Stephanie Day; Mark D Wright; Lily Stojanovska; Vasso Apostolopoulos
Journal:  J Drug Deliv       Date:  2013-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.